Immunotherapy is a collection of approaches that trains and directs the body’s natural immune system to attack cancer cells. In the last few years alone, more than 2,000 new immunotherapy agents have entered development. Unfortunately, few are focused on multiple myeloma. The ones that are don’t work for every patient. We are focusing on several specific types of immunotherapy that show promise for myeloma, including chimeric antigen receptor T-cell (CAR-T) therapy, vaccines, and monoclonal antibodies.

To fulfill the promise of immuno-oncology (IO) in multiple myeloma, we will address three core areas:

  1. Immune Atlas: We will establish a gold standard immune profiling platform for myeloma research and clinical studies. The platform will also generate robust immune data that drives research..
  2. Clinical Acceleration: We will accelerate new discoveries and clinical insights in immunology through novel studies, including platform trials, in order to get new therapies to patients more quickly
  3. Prevention: We will generate data to better understand early stage (smoldering multiple myeloma) patients to delay and ultimately prevent disease progression to improve patient outcomes.

Read about the priorities the MMRF and our partners set for making progress in these areas at the MMRF Immune Summit 2019.